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The CFTR splicing mutation 3849 1 10 kb C 3 T cre-
ates a novel donor site 10 kilobases (kb) into intron 19 of
the gene and is one of the more common splicing muta-
tions that causes cystic fibrosis (CF). It has an elevated
prevalence among patients with atypically mild disease
and normal sweat electrolytes and is especially promi-
nent in Ashkenazi Jews. This class of splicing mutations,
reported in several genes, involves novel splice sites
activated deep within introns while leaving wild-type
splice elements intact. CFTR cDNA constructs that mod-
eled the 3849 1 10 kb C3 T mutation were expressed in
3T3 mouse fibroblasts and in CFT1 human tracheal and
C127 mouse mammary epithelial cells. In all three cell
types, aberrant splicing of CFTR pre-mRNA was compa-
rable to that reported in vivo in CF patients. Treatment
of the cells with 2*-O-methyl phosphorothioate oligori-
bonucleotides antisense toward the aberrant donor and
acceptor splice sites or to the retained exon-like se-
quence, disfavored aberrant splicing and enhanced nor-
mal processing of CFTR pre-mRNA. This antisense-me-
diated correction of splicing was dose- and sequence-
dependent and was accompanied by increased
production of CFTR protein that was appropriately gly-
cosylated. Antisense-mediated correction of splicing in
a mutation-specific context represents a potential gene
therapy modality with applicability to many inherited
disorders.
Cystic fibrosis (CF)1 is an inherited disorder characterized by
multi-organ involvement and substantial heterogeneity in the
presentation of disease (1). At a molecular level, the pathogen-
esis of CF is attributable in part to over 800 known mutations2
within the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene, which interfere with the processing or integ-
rity of the CFTR protein, a cAMP-activated chloride channel
(3–6). To the extent that mutations within the CFTR gene
permit residual chloride channel activity, a milder phenotype
typically results.
Approximately 14% of the deleterious mutations known to
cause cystic fibrosis interfere with mRNA splicing, a frequency
comparable to that reported for other inherited disorders (3,
7).2 Of the splicing mutations reported, the great majority
disrupt either the splice acceptor or splice donor sites that
demarcate the 59 and 39 ends of each exon, respectively, and
drive the exclusion of that exon from the mature transcript.
Splicing may also be derailed by mutations within introns
that create novel splice sites, resulting in the inappropriate
inclusion of non-coding sequence. This often occurs close to
exons, but may also occur deep within introns, creating either
a novel donor or acceptor site that, in conjunction with a nearby
cryptic splice site of the opposite polarity, defines a novel,
aberrant exon that the spliceosome recognizes and includes
into the mature message. Several examples of this mutational
mechanism have been shown to underlie inherited diseases,
such as b-thalassemia (8–12), CF (13, 14), neurofibromatosis
type 1 (15), multiple breast tumors (16), dihydropteridine re-
ductase deficiency (17), maple syrup urine disease (18), Alport
syndrome (19), ornithine d-aminotransferase deficiency (20),
b-glucuronidase deficiency (21), ataxia-telangiectasia (22), con-
genital lipoid adrenal hyperplasia (23), and obesity in mice (24,
25). The true prevalence of mutations of this kind is probably
underestimated since few laboratories analyze intron se-
quences far from coding regions.
One of the deep intron mutations that cause CF by the above
mechanism, 3849 1 10 kb C3 T, is relatively common, with an
overall frequency of 1–2% and an elevated prevalence in indi-
viduals of Ashkenazi Jewish ancestry (26).2 It is also the most
common mutation among CF patients with normal sweat elec-
trolytes and mild disease (13), as well as among fertile CF men
(13, 27). This mutation generates an aberrant 59 splice site
deep in intron 19 of CFTR pre-mRNA and activates a cryptic 39
splice site 84 nucleotides upstream. Importantly, 3849 1 10 kb
C3 T and other alleles of this class do not alter wild-type splice
sites. With these sequences intact, the mRNA involved can be
regarded as retaining the potential for normal splicing, if usage
of the aberrant splice sites could be inhibited.
Kole et al. (28–30) have previously demonstrated that anti-
sense oligonucleotides or RNAs with an affinity for aberrant 59
and 39 splice sites underlying b-thalassemia deterred usage of
these elements by the spliceosome in favor of the intact, wild-
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type splice sites, promoting normal splicing patterns and cor-
rect expression of the b-globin gene. Here we report the appli-
cability of this approach to the correction of aberrant splicing in
the context of CF with enhanced synthesis and processing of
CFTR protein.
EXPERIMENTAL PROCEDURES
Vector Construction—CFTR expression vectors were constructed
that contain a truncated intron 19 harboring the 3849 1 10 kb C 3 T
locus. The mini-intron was assembled from three PCR fragments of
genomic sequence derived from the native CFTR intron 19: an XhoI-
HindIII fragment encompassing the 39 end of exon 19, the splice donor
site, and the initial sequences of intron 19; a HindIII-SalI fragment
containing the central region of intron 19 including the 3849 1 10 kb C
3 T and its upstream cryptic acceptor site (this fragment was amplified
with or without the 3849 1 10 kb C 3 T mutation); a SalI-BamHI
fragment straddling the intron 19-exon 20 junction that contains the
native acceptor splice site and the polypyrimidine tract preceding exon
20. To improve the efficiency of splicing of the constructs in cell culture,
the polypyrimidine tract was optimized by the substitution of pyrimi-
dines for three interrupting purines.
Ordered ligation of these fragments into a 415-bp mini-intron was
achieved as depicted in Fig. 1A. The mini-intron 19 was subsequently
incorporated into the LCFSN CFTR vector containing the intact coding
region of CFTR and the Geneticin (G418) resistance genes, controlled
by a retroviral LTR promoter (31) using a PCR-based mutagenesis
protocol (32, 33). The details of the construction are available on
request.
Intron-containing constructs were digested with HphI to detect the
presence or absence of the mutation (13) and further by direct sequenc-
ing (34). The modified vectors selected for further studies were LCFSN-
3849wt (wild-type mini-intron) and LCFSN-3849mut (mutant mini-
intron). The wild-type and mutant mini-introns were also inserted in
the cytomegalovirus-driven, CFTR expression vector, pCF1-CFTR (35)
by similar procedures.
Cell Culture—Mouse NIH 3T3 fibroblasts were grown in DMEM-H
(high glucose) supplemented with 10% fetal calf serum. The immortal-
ized human tracheal epithelial line, CFT1 (36), was grown in serum-
free Ham’s F-12 supplemented with factors described elsewhere (37).
C127 mouse mammary epithelial cells were grown in DMEM-L (low
glucose) supplemented with 10% fetal calf serum. Human T84 colorec-
tal carcinoma cells, which express high levels of CFTR, were used for
controls and were grown in DMEM/F-12 supplemented with 5% new-
born bovine serum. All culture media contained penicillin/streptomycin.
Construction of Stable Cell lines—3T3- or CFT1 cells were stably
transfected with either LCFSN-3849wt or LCFSN-3849mut plasmids
using LipofectAMINE (Life Technologies, Inc.) and selection with G418
(580 and 150 mg/ml G418, respectively, for the selection and mainte-
nance of 3T3- and CFT1-derived cell lines). 3T3 and CFT1 clonal cell
lines containing the wild-type and mutant mini-introns ((3T3-WT8,
3T3-M11, CFT1-WT, CFT1-M15) were selected for further study. Con-
struction of C127-derived mouse mammary epithelial cell lines was
accomplished by co-transfection of native or modified pCF1-CFTR ex-
pression constructs with the pMEP4 plasmid (Invitrogen), which con-
fers hygromycin resistance. Selection proceeded in 500 mg/ml hygromy-
cin. The C127 cell line stably expressing the DF508 CFTR mutant was
a gift from Genzyme Genetics (Framingham, MA) (38).
Antisense Oligoribonucleotides: Design and Usage—Antisense oligo-
nucleotides were 18 or 19-mer 29-O-methyl oligoribonucleoside phos-
phorothioates (Hybridon Inc., Milford, MA, and Midland Certified Re-
agent Co. Woodland, TX) (Table I). They were targeted to either the
novel splice donor site, the cryptic splice acceptor site or to a region
within the 84-bp aberrant exon that includes an in-frame stop codon
(Fig. 1B). Anti-b-globin or anti-CFTR oligonucleotides with two mis-
matched nucleotides were used as negative controls (Table I).
Transfection with Antisense Oligonucleotides (29)—50–100 3 103 of
3T3-M11 cells were plated in each well of a 24-well plate 48 h prior to
treatment with the oligonucleotide. Antisense oligonucleotides were
complexed at room temperature with either 6% LipofectAMINE or 4%
DMRIE-C solutions in 200 ml of serum-free Opti-MEM (Life Technolo-
gies, Inc.) for 15–30 min. After dilution to 1 ml with Opti-MEM, each
mixture was added to cells (pre-washed with Opti-MEM to remove
serum) and incubated for 3–5 h. Subsequently, the transfection mixture
was replaced with serum containing growth media and cells were har-
vested 24–48 h after transfection. The antisense oligonucleotide con-
centrations ranged from 0 to 1.0 mg/ml.
Oligonucleotide treatment of CFT1 cell lines with antisense oligonu-
cleotides was similar and used 5% DMRIE-C in Opti-MEM, 3-h trans-
fections, and harvesting 24 h after transfection. Sodium butyrate, pre-
viously shown to boost CFTR transgene expression in 3T3-derived cells
(39), was added (30 mM) to CFT1 cells for 24 h after transfection. For
C127 cell lines, transfection was performed with 2.5% ExGen500 (MBI
Fermentas) in Opti-MEM for 3 h. Cells were harvested 24 h after
transfection.
RNA Isolation and RT-PCR Analysis—Cells were rinsed once with
Hank’s balanced salt solution and lysed at room temperature for 5 min
with 1 ml of TRI reagent (MRC, Inc.; Cincinnati, OH) per well of
transfected cells. Total cellular RNAs were purified according to man-
ufacturer’s instructions, and concentrations were measured via spec-
trophotometry at 260 nm. All RNAs were stored at 220 °C.
RT-PCR was performed using the rTth kit (Perkin-Elmer) with 0.2–
0.3 mg of RNA per reaction. The RT reaction was performed in 10 ml for
15 min at 70 °C. [a-32P]dATP was incorporated during the subsequent
PCR, performed in 50 ml (95 °C for 3 min, followed by 18–24 cycles of
65 °C for 1 min and 95 °C for 1 min).
Primers (A, 59-ATCCAGTTCTTCCCAAGAGGC-39; B, 59-TCTTCC-
CAAGAGGCCCACCCTCTG-39, C, 59-TCTTCCCAAGAGGCCCACCAT-
TTT-39; D, 59-CCAAATGACTGTCAAAGATCTCACAGCA-39) were de-
signed to detect splicing isoforms arising from processing of the mini-
intron as depicted in Figs. 2–7. RT-PCR products (typically 20 ml from
the 50-ml RT-PCR sample representing reaction products derived from
120 ng of RNA template) were electrophoresed on 8% polyacrylamide
(29:1, acrylamide:bisacrylamide) non-denaturing gels (29), which were
dried and autoradiographed for 1–24 h. RT-PCR products derived from
T84 RNA template served as a positive control for wild-type splicing. If
necessary for further analysis, bands of interest were excised from dried
polyacrylamide gels, eluted, re-amplified using primers A and D and
sequenced (34).
Western Blots—C127-derived stable cell lines were grown to ;80%
confluence on 10-cm plates and transfected with antisense oligonucleo-
tides as described above. For protein isolation, cells were rinsed twice
with Hank’s balanced salt solution and lysed with 1 ml of 3% SDS, 60
mM Tris, pH 6.8, 1 mM EDTA, 6% sucrose, 100 mg/ml phenylmethylsul-
fonyl fluoride, 1–2 mg/ml aprotinin, and 1–2 mg/ml leupeptin. Samples
were made up to 50 mM dithiothreitol, and Pyronin Y tracking dye was
added prior to electrophoresis on 7% SDS-polyacrylamide gels. Proteins
were electroblotted to a nitrocellulose membrane and probed with a
polyclonal anti-CFTR antibody (a-1468) (40) and a horseradish peroxi-
dase-conjugated secondary antibody (Amersham Pharmacia Biotech).
Detection utilized the ECL kit (Amersham Pharmacia Biotech) and
luminography.
RESULTS
Restoration of Correct CFTR Splicing in 3T3-CFTR Cell
Line—In order to model the 3849 1 10 kb C 3 T splicing
mutation in cell culture, a 415-bp mini-intron was created by
the ordered ligation of three fragments derived from the native
22-kb intron 19 of CFTR (see Fig. 1A and “Experimental Pro-
cedures”). The construct retained intron 19 native splice sites
and approximately 240 bp of sequence bracketing the mutation
locus and the cryptic acceptor splice site activated by the mu-
tation. The ligated fragment was accurately inserted at the
exon 19-exon 20 junction of the CFTR cDNA portion of the
LCFSN expression vector (31). The expression of CFTR gene
from this vector is driven by retroviral (murine leukemia virus)
LTR promoter. The resulting constructs were used to generate
3T3- and CFT1-based cell lines, which constitutively expressed
either the wild-type or the mutant mini-intron containing
CFTR genes.
Fig. 2 shows RT-PCR analysis of total RNA from a 3T3-based
stable cell line (3T3-M11) expressing the 3849 1 10 kb C 3 T
CFTR construct. The cell line did not express detectable levels
of correctly spliced CFTR mRNA (Fig. 2A, lanes 2 and 8) as
shown by a lack of the RT-PCR band co-migrating with that of
the control CFTR mRNA from T84 cells (Fig. 2A, lane 1). The
correctly spliced fragment was generated after treatment of the
3T3-M11 cells with antisense oligonucleotides (Table I) com-
plexed with cationic lipid carriers and targeted to either the
aberrant cryptic acceptor site (Fig. 2A, lanes 2–7) or the donor
site (Fig. 2A, lanes 8–13). For both oligonucleotides the effects
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were dose-dependent. Dose-dependent correction of CFTR
pre-mRNA splicing was also observed when both 39 and 59
splice site targeted antisense oligonucleotides were combined
and used for cell treatment (Fig. 2B, lanes 2–5). Lack of cor-
rectly spliced CFTR mRNA in cells treated with an oligonu-
cleotide antisense to the human thalassemic b-globin IVS2–
654 aberrant donor site (29), which has no affinity for the CFTR
transgene’s aberrant splice sites, shows sequence specificity of
the effects (Fig. 2B, lanes 6–8). These results indicate that the
antisense oligonucleotides prevented utilization of the aberrant
splice sites by the spliceosome and forced it to reutilize the
existing correct splice sites, thereby restoring correct splicing of
CFTR pre-mRNA.
Characterization of RT-PCR Products; Identification of a
Cryptic 59 Splice Site in Intron 19 of CFTR Gene—RT-PCR of
total RNA expressed in 3T3-M11 cell line should in principle
produce a single band of 203 bp representing aberrantly spliced
3849 1 10 kb C 3 T CFTR mRNA (Fig. 2A, primers D and A).
After correction of splicing with antisense oligonucleotides, a
119-bp band representing correctly spliced mRNA should also
appear. However, in oligonucleotide-treated cells, an array of
bands was generated, complicating identification of aberrant
products. Thus, we have designed a series of primers, dia-
grammed in Fig. 3, intended to amplify either all CFTR
mRNAs, only correctly spliced mRNAs, or only aberrant
mRNAs.
RT-PCR (primers D–A, Fig. 3) of RNA from oligonucleotide-
treated cells (the same RNA as analyzed in Fig. 2A, lane 13)
detected both the correctly spliced CFTR mRNA that co-mi-
grates with T84-derived mature splicing products (Fig. 3, lane
1) and additional species, which presumably included the ab-
errantly spliced mRNAs (Fig. 3, lane 2). The wild-type-specific
primers, D–B, amplified only the correctly spliced mRNA, as
expected (Fig. 3, lane 4), while the aberrant specific primers,
D–C, amplified a doublet of bands migrating, at ;240 and
;200 bp, respectively, the smaller of which closely approxi-
mated the 196-bp fragment detected in vivo (13) (Fig. 3, lane 5).
The nature of the heavier of the two fragments was not imme-
diately known.
To clarify the identity of the products arising from splicing of
the CFTR transgenes, RT-PCR generated bands were re-am-
plified with primers A and D and sequenced. The fragment that
co-migrated with the control for wild-type splicing was con-
firmed to be the product of correct splicing, whereas the smaller
of the two heavy bands included the 84-bp insertion reported in
vivo (13) and therefore represented the expected aberrantly
spliced CFTR mRNA. The heavier fragment with an effective
mobility of ;240 bp contained, in addition to the sequences
found in the smaller aberrant fragment, the first 40 bp of intron
19 inserted between the 39 end of exon 19 and the 59 end of the
84-bp aberrant insertion. Analysis of the sequence at the 59
region of native intron 19 of CFTR gene showed that a previ-
ously unrecognized cryptic splice donor site (CAuGTAAGT) re-
sides at position 3849 1 41. Thus, in the 3T3-M11 cell line, the
mini-intron undergoes two aberrant splicing events, inclusion
FIG. 1. A, modification of LCFSN CFTR expression vector to include
mini-intron 19. Three fragments of genomic sequence derived from the
native or 3849 1 10 kb C 3 T mutated CFTR intron 19 were obtained
by PCR. The fragments were cleaved with appropriate restriction en-
zymes (indicated at the upper part of panel A), ligated, amplified with
tailed primers complementary to exon sequences near the native splice
junctions (59ss, 39ss, short vertical lines), and inserted into LCFSN
vector (lower part of panel A) linearized at the exon 19-exon 20 border
with PflM1 (see “Experimental Procedures” for more details). The po-
sition of the mutation locus (*), the cryptic 39 splice site (39cr), and the
nucleotide lengths of appropriate fragments are indicated. The open
boxes of the lower part of panel A represent the CFTR cDNA and
Geneticin resistance gene. LTR, murine leukemia virus LTR promoter.
B, splicing pathways of LCFSN-3849mut (mutant mini-intron)
pre-mRNA. Boxes, exons; heavy line, intron. Thin solid and dashed lines
represent aberrant and corrected splicing pathways, respectively.
Heavy short bars, antisense oligonucleotides targeted to the aberrant 39
splice site, the stop codon, and the aberrant 59 splice site, respectively
(see “Experimental Procedures” for more details and Table I for oligo-
nucleotide sequences).
FIG. 2. Correction of aberrant CFTR splicing in 3T3-M11 cells
by antisense oligonucleotides. A, 3T3M11 cells were treated with
antisense oligonucleotides (39AS or 59AS) targeting the aberrant accep-
tor and donor splice sites, respectively. Total RNA was isolated and
subjected to RT-PCR, and the products were analyzed by polyacryl-
amide gel electrophoresis. The products and the primers used in RT-
PCR are depicted below the panels (see “Experimental Procedures”).
Lane 1, RNA from T84 cells, positive control for wild-type RNA splicing
(T84); lanes 2–7, correction of aberrant splicing by 39AS; lanes 8–13,
correction of aberrant splicing by 59AS; lane 14, water blank. The
length, in nucleotides, of RT-PCR products derived from correctly (119)
and aberrantly (243, 203) spliced CFTR mRNAs is indicated. Concen-
trations (mM) of antisense oligonucleotides are shown at the top. Unless
otherwise indicated similar designations are used in the remaining
figures. B, lanes 2–5, correction of aberrant splicing in 3T3-M11 cells in
response to dual antisense oligonucleotide treatment targeting both the
aberrant splice donor or cryptic splice acceptor sites; lanes 6–8, absence
of splicing correction upon treatment with antisense oligonucleotide
targeting the b-globin, IVS2–654 aberrant donor site (29).
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of the 84 nucleotide “exon” and utilization of a cryptic 59 splice,
resulting in a 243-bp splice isoform.
The products of correct splicing generated in 3T3-M11 cell
line by antisense oligonucleotide treatment were additionally
identified by RT-PCR analysis with primers D–B (Fig. 4, lanes
2–7). The RNAs analyzed in this figure are the same as those in
Fig. 2A (lanes 8–13). A single prominent band co-migrating
with the RT-PCR product of T84-derived native CFTR mRNA
(Fig. 4, lane 1) represents correctly spliced CFTR mRNA and
shows with great clarity the dose response of CFTR splicing
correction to antisense treatment.
Correction of CFTR Splicing in CFT1 Cells—To more closely
approximate the cells that would constitute actual targets if
antisense oligonucleotides were used for treatment of cystic
fibrosis, the CFT1-based cell lines carrying the modified CFTR
transgenes, LCFSN-3849wt or LCFSN-3849mut, were devel-
oped. The CFT1 cells, a human papilloma virus-immortalized
human tracheal epithelial cell line derived from a CF patient,
have retained their differentiated phenotype yet lost the en-
dogenous CFTR expression, eliminating a background that
might otherwise have obscured detection of antisense-mediated
effects (36).
Similar to 3T3-M11 cells, the monoclonal CFT1-M15 cell line
exhibited the dose- and sequence-dependent correction of mod-
ified CFTR pre-mRNA splicing by antisense oligonucleotide
targeted to the 3849 1 10 kb C 3 T donor splice site (Fig. 5,
lanes 2–6). The CFT1-M15 line differed from the 3T3-M11
counterpart in that the pair of bands regarded as products of
aberrant splicing was either absent or present at much lower
levels. It seemed possible that in these cells the aberrantly
spliced CFTR mRNA was much less stable than the correctly
spliced one because the ochre stop codon within the aberrant
exon provided a recognition element for the nonsense-mediated
RNA decay machinery (41). Thus, an antisense oligonucleotide
targeted to the sequence surrounding the premature stop codon
was designed to test if blocking this codon might promote
appearance of the aberrant bands. An alternative possibility
that correct splicing might be promoted by an antisense oligo-
nucleotide that prevents binding of the splicing factors to the
84 nucleotides of the aberrant exon, thereby interfering with
the definition of the exon by the splicing machinery (42), was
also considered.
Although the “anti-stop” oligonucleotide showed no utility for
increasing the stability of aberrant transcripts, it did promote
correct splicing as efficiently as the antisense oligonucleotides
targeted to aberrant splice sites, i.e. equivalent concentrations
(0.3 mM) of the 59 AS, 39AS, or anti-stop oligonucleotides were
comparably effective (Fig. 6, lanes 3–5). Interestingly, dual (or
even triple) treatment with all possible AS oligonucleotide com-
binations appeared more effective than single oligonucleotide
treatment, suggesting additive or synergistic effects among the
TABLE I
Sequences of antisense oligonucleotides
AS, antisense. Asterisks (*) indicate mismatched bases relative to target sequences. Underlined bases mark the location of the in-frame ochre
stop codon within the 84-bp aberrant insert. b-Globin IVS2–654 antisense oligonucleotide as reported (29).
59AS Novel donor site 59-GUCUUACUCACCAUUUUA-39
59mis Mismatched control for 59AS 59-GUCUUCCUCACCCUUUUA-39
* *
39AS Cryptic acceptor site 59-CAAGUCAACUGAAAUUUAG-39
39mis Mismatched control for 39AS 59-CAAGUCCACUGAACUUUAG-39
* *
Anti-stop In-frame stop codon 59-CUUGUAAUUAUUUUUACAU-39
b-Globin IVS2–654 (beta) b-Globin novel donor site 59-GCUAUUACCUUAACCCAG-39
FIG. 3. Differential RT-PCR analysis identifies wild-type and
aberrant CFTR splicing products. Lanes 1 and 3, T84 RNA; lanes 2,
4, and 5, RNA from 3T3-M11 cells treated with 0.3 mM 59 AS (same RNA
as in lane 13, Fig. 2A). Primers D and A (lanes marked A), all CFTR
mRNA isoforms are amplified. Primers D and B (lanes B), RT-PCR
specific for correctly spliced CFTR mRNA. Primers D and C (lane C),
aberrant-specific RT-PCR. The length, in nucleotides, of the resulting
RT-PCR products is indicated.
FIG. 4. Dose responsiveness of antisense-mediated correction
of aberrant splicing in 3T3-M11 cells demonstrated with wild-
type specific RT-PCR. Lanes 2–7, correction of aberrant splicing in
3T3-M11 cells in response to antisense treatment with oligonucleotide
59AS, complementary to the aberrant 59 donor splice site. Same RNAs
as in lanes 8–13 of Fig. 2A.
FIG. 5. Antisense-mediated correction of aberrant splicing in
the CFT1-M15 cell line. Lanes 2–6, RNA from cells treated with
oligonucleotide 59AS, complementary to the aberrant 59 donor splice
site.
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oligonucleotides (Fig. 6, lanes 6–9).
Restoration of Correct CFTR Gene Expression in C127
Cells—Although expression of aberrant CFTR mRNA and cor-
rection of splicing of CFTR pre-mRNA were clearly detectable
in 3T3 and CFT1 cell lines, we were unable to detect in oligo-
nucleotide-treated cells the expected correct CFTR protein.
Assuming that this was due to a low level of expression of the
transgenes in both cell lines, we have explored another cell
line-vector combination as a means of attaining sufficiently
high levels of CFTR expression.
C127 mouse mammary epithelial cells divide rapidly and
strongly express CFTR protein when transfected with the
pCF1-CFTR construct, in which expression of CFTR cDNA is
driven by a strong immediate early cytomegalovirus promoter
(35, 40). Transfection of these cells with either native pCF1-
CFTR (no intervening introns) or its modified counterpart har-
boring the wild-type mini-intron 19 (pCF1-CFTRwt) resulted in
one prominent RT-PCR product representing mature CFTR
transcripts (data not shown). A stable cell line (C127-M7) har-
boring the pCF1-CFTRmut construct (with mutated mini-in-
tron 19) expressed the aberrant CFTR mRNA with greater
efficiency than either the 3T3- or CFT1-derived cell lines and
produced minimal levels of correct mRNA in the absence of
antisense oligonucleotides (Fig. 7, lane 2).
The C127-M7 cells were transfected with varying concentra-
tions (0–0.5 mM) of the 59 AS or anti-stop antisense oligonu-
cleotides using ExGen500 as delivery agent. As shown with the
previous cell lines, C127-M7 cells produced correctly spliced
CFTR mRNA in a dose-responsive manner when treated with
the oligonucleotides individually (Fig. 7, lanes 2–7 and 9) or in
combination (Fig. 7, lane 10). Additionally, treatment with a
mismatched oligonucleotide, with partial homology for the ab-
errant donor site, was much less effective at promoting correct
splicing, confirming sequence specificity of the effect (Fig. 7,
lane 8). Identical results were attained using a mismatched
oligonucleotide with partial homology for the cryptic splice
acceptor site (data not shown).
Expression of the aberrant transgene in C127-M7 cells as
well as its responsiveness to antisense treatment were suffi-
ciently robust to assess the synthesis of CFTR protein in oligo-
nucleotide-treated cells by Western blot analysis (see “Experi-
mental Procedures”). Fig. 8 demonstrates an increase in CFTR
protein production with increasing dose of antisense oligonu-
cleotides targeted to the aberrant 59 splice site (Fig. 8, lanes
2–4). As with RT-PCR analysis, it is apparent that the treat-
ment with a mixture of two individually effective antisense
oligonucleotides, 59 AS and anti-stop, is superior, on an equimo-
lar basis, to single oligonucleotide treatment (Fig. 8, lane 5). As
expected, neither the mismatched oligonucleotide, nor anti-
sense oligonucleotide targeted to the human b-globin IVS2–
654 splice site were effective at promoting translation of CFTR
protein (Fig. 8, lanes 6 and 7, respectively). C127 parental cells
expressing modified pCF1-CFTR harboring a wild-type mini-
intron (pCF1-CFTRwt) were also shown to permit CFTR pro-
tein formation (Fig. 8, lane 8).
The CFTR protein generated in oligonucleotide-treated cells
co-migrated on the gel with CFTR expressed in C127 cells
harboring the pCF1-CFTRwt construct or in T84 cells (Fig. 8,
lanes 8 and 9, respectively). The migration of CFTR protein
derived from a C127 cell line expressing the common DF508
CFTR mutant was faster (Fig. 8, lane 10). This result indicates
that, in contrast to DF508 CFTR, glycosylation of which is
known to be defective (43), the CFTR protein generated by
antisense oligonucleotides is wild-type and fully glycosylated.
DISCUSSION
3849 1 10 kb C 3 T is a member of a class of splicing
mutations that, rather than disrupting existing splice sites,
create novel ones that are erroneously recognized by the splic-
ing machinery (8–25). Usage of such splice sites results in the
abnormal inclusion of intron sequences in the mature tran-
scripts with a wide range of clinical consequences. The exon-
shuffling theory (44) proposes that introns serve as reservoirs
of new coding sequence and evolutionary potential and muta-
tions like 3849 1 10 kb C 3 T are mechanistically compatible
FIG. 6. Increased correction of CFTR pre-mRNA splicing in
CFT1-M15 cells by combined antisense oligonucleotides. Lanes
1–9, CFT1-M15 cells treated with different combinations of antisense
oligonucleotides (described above the lanes). FIG. 7. Antisense-mediated correction of aberrant splicing in
C127-M7 cells. The cells were treated with the following: lanes 2–7,
59AS oligonucleotide; lane 8, 0.3 mM mismatched 59 AS (negative con-
trol); lane 9, 0.3 mM anti-stop AS; lane 10, 0.15 mM each 59AS and
anti-stop oligonucleotide.
FIG. 8. Detection in C127-M7 cells of appropriately glycosy-
lated CFTR protein generated by antisense oligonucleotides.
Total cellular protein was analyzed by immunoblotting and detection
with a polyclonal anti-CFTR antibody (see “Experimental Procedures”
for details). Lane 1, M, protein size markers (molecular mass in kDa
indicated on the left). Lanes 2–4, C127-M7 cells treated with 0, 0.02,
and 0.2 mM 59 AS, respectively. Lane 5, treatment with 0.1 mM each, 59
AS oligonucleotide targeting aberrant 59 site and the in-frame stop
codon oligonucleotide (anti-stop). Lanes 6 and 7, negative controls with
0.2 mM mismatched 59AS and b-globin IVS2–654 (beta) oligonucleo-
tides, respectively. Lane 8, C127 cells transfected with pCF1-CFTRwt
construct. Lane 9, T84 cells (positive control). Lane 10, C127 cells
expressing pBPV-CFTR-DF508 (38).
Repair of Mutated CFTR Pre-mRNA 36197
with this theory. From the standpoint of immediate clinical
consequences, however, molecular derangements of this class
must be detrimental in the vast majority of individuals.
The likelihood that an RNA sequence will be recognized by
the spliceosome depends chiefly on how well it approximates
the consensus splice site sequence. The relation between the
consensus sequence and a given splice site may be expressed
numerically using the scoring system of Shapiro and Senapa-
thy (45). Relative to the consensus splice site score of 100, 3849
1 10 kb C 3 T creates a novel donor site with a score of 88.9;
the score of the non-mutated sequence at this site is 70.6. By
comparison, the native intron 19 donor and acceptor splice sites
have scores of 83.2 and 86.7, respectively. This analysis sug-
gests that the novel splice site should be preferred over the
native ones by the splicing machinery. Moreover, and probably
more importantly, the novel splice site in conjunction with the
cryptic splice site located 84 nucleotides upstream in the intron
creates an exon-like sequence. The exon definition mechanism
predicts that such sequence should be efficiently included in
the spliced mRNA (42). Interestingly, despite the high score of
the novel donor splice site and creation of the aberrant exon,
the impediment to normal splicing is not absolute. In vivo, but
not in vitro, as shown by our results, approximately 8% of the
CFTR transcripts are normal length (13). This low level of
wild-type mRNAs is thought to account for the mild, if variable,
phenotypes in patients with the 3849 1 10 kb C3 T mutation
(13, 27, 46, 47). The retention of wild-type splice sites on 3849
1 10 kb C 3 T alleles not only permits low levels of normal
splicing but also suggested a mechanism by which wild-type
splicing could be restored. If usage of the aberrant splicing
elements were prevented by antisense oligonucleotides, it
seemed likely that the spliceosome will revert to normal utili-
zation of the native splice elements.
Using two different CFTR cDNA expression vectors, LCFSN
and pCF1-CFTR, in three different cell lines (3T3, CFT1, and
C127), we have demonstrated that antisense oligonucleotides
complementary to either the aberrant donor or the cryptic
acceptor splice sites promoted the formation of correctly spliced
CFTR mRNA. This corrective effect was specific for the oligo-
nucleotides with full complementarity to the 18 bp of sequence
bracketing each novel splice site. Oligonucleotides with two
nucleotide mismatches and an oligonucleotide of wholly unre-
lated sequence showed no efficacy for the correction of splicing.
The correction of aberrant splicing in multiple cellular con-
texts speaks to the potential broad applicability of this thera-
peutic modality. This approach has been also shown to be
effective in correction of splicing of human thalassemic b-globin
pre-mRNAs (28–30) and in modification of splicing of dystro-
phin genes (48, 49).
Patients with 3849 1 10 kb C 3 T reportedly produce one
major aberrant mRNA isoform reflecting the inclusion of 84 bp
of intron sequence (13). RT-PCR analysis of splicing in the 3T3-
and C127-derived mutant cell lines, however, identified two
bands associated with aberrant processing. One represented
the expected 84-bp insertion, while the second band incorpo-
rated the first 40 bp of intron 19 due to splicing at a cryptic
splice donor site (CAuGTAAGT) at position 3849 1 41, which,
surprisingly, is present but does not appear to be active, in
native intron 19 sequence. This site has a Shapiro-Senapathy
score of 79.4 in primates and 80.1 in rodents (45) and, if
activated, should disrupt the reading frame of the mature
message. It is possible that the novel sequence context within
the mini-intron may be responsible for its use and/or that the
heterologous expression of the constructs in murine cells that
do not normally express CFTR gave rise, in vitro, to this unex-
pected splicing pathway. However, since this splice site is pres-
ent in the native CFTR intron 19, one must consider that its
activation may occur in some patients or in specific tissue
contexts. If this is true, the level of usage of this cryptic donor
site may contribute to variable disease severity in patients with
identical mutational genotypes of the CFTR gene.
The anti-stop oligonucleotide that anneals to the vicinity of
the ochre stop codon in the aberrant exon promoted wild-type
splicing. This result, which was equally apparent in both
CFT1- and C127-derived mutant cells, should be viewed in
light of the exon definition model that postulates interaction
between spliceosome components bridging an exon (42). An
oligonucleotide that sterically inhibits this bridging would im-
pair recognition of the exon as sequence to be retained in the
mature message. Blocking of the premature stop codon itself
was probably not pertinent to this effect.
Superior correction of splicing was seen when two rather
than one antisense oligonucleotide were transfected in concert,
e.g. targeting the 59 and 39 splice sites simultaneously. Presum-
ably one oligonucleotide corrects splicing among those tran-
scripts left untouched by the other oligonucleotide. A rigorously
quantitative assessment will be required to determine if the
effect is synergistic or merely additive.
It is logical to assume a priori that correction of splicing
would be accompanied by increased production of normal pro-
tein. The ribosome should translate correctly processed CFTR
mRNAs equally without regard to how they came to be cor-
rectly spliced. C127 cells stably transfected with the aberrant
pCF1-CFTR transgene produced CFTR protein upon treatment
with the same oligonucleotides shown to correct splicing. The
increase in detectable protein was both sequence- and dose-de-
pendent, with dual oligonucleotide treatment associated with
the highest level of protein. Furthermore, we note that the
CFTR protein formed in response to antisense oligonucleotide
treatment was appropriately glycosylated, suggesting that
CFTR polypeptide processing beyond simple translation has
also occurred, presumably leading to cell surface expression
and chloride conductance.
The potential for antisense-mediated approaches to achieve
utility in the clinical arena will depend on several factors.
Splicing mutations that evoke aberrant inclusion of intron se-
quence are currently regarded as infrequent. Although several
mutations that fit this category have been reported (8–25),
there is likely a bias against their identification. Typically,
mutation screening targets coding regions and adjacent splice
sites, whereas more cumbersome RNA-based analyses are best
suited to discern deep intron mutations. The mutations iden-
tified thus far may represent the tip of the iceberg.
Each of the examples cited (8–25), including 3849 1 10 kb C
3 T, involve a novel splice site in proximity to a cryptic splice
site of the opposite polarity. In principle, these can occur at
anyplace within an intron. In contrast, many other intronic
mutations create splice donor and acceptor sites proximal to
exons, leading to the inclusion of intron sequences adjacent to
those exons into the mature message (50–57). As with 3849 1
10 kb C 3 T, wild-type splicing elements remain intact, mak-
ing these aberrant alleles potential substrates for antisense-
mediated correction as well, as long as no steric hindrances
with the spliceosome occur. This approach has been tested in
vitro in the context of thalassemic mutations of human b-globin
gene (28, 58).
29-O-Methyl oligoribonucleoside phosphorothioates as anti-
sense oligonucleotides have high affinity for their target se-
quences, are markedly resistant to intracellular degradation,
and, when complexed to their target, will not promote RNase
H-mediated cleavage of targeted RNA (59). With such obvious
technical utility, it is important that neither the oligonucleo-
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tides nor the delivery vehicle is unduly detrimental to the
treated cells. Strong antisense-mediated correction has been
demonstrated without a dramatic impact on cell morphology or
viability. Furthermore, an argument that antisense oligonu-
cleotides might have unforeseen, nonspecific effects on splicing
and, consequently, the expression of a multitude of other genes
is not supported by gross assessment of cell viability, morphol-
ogy, and growth rates, all of which appear normal. In view of
these promising results, further experimentation and optimi-
zation should encompass ex vivo or in vivo studies in animal
models.
The potential for antisense pharmaceuticals to treat human
disease depends upon the safe delivery of oligonucleotides at
therapeutic doses to appropriate tissues. Many animal studies
have demonstrated efficacious delivery of oligonucleotides
through systemic treatment (reviewed in Ref. 60), and this
approach might prove equally valid for treatment of CF. Alter-
natively, aerosol delivery of the antisense oligonucleotides di-
rectly into CF lungs may efficiently target the impaired tissues.
Importantly, treatment with antisense oligonucleotide aerosols
markedly reduced allergic response in lungs of rabbits model-
ing adenosine-mediated hyper-responsiveness (61). The effi-
cient, low dose delivery of potentially therapeutic antisense
appeared to be facilitated by weakly cationic lung surfactants,
which are known to recycle between type II pneumocytes and
the air-liquid interface in the lung (2).
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